DK3302523T3 - Sammensætning til behandling af vævslæsioner - Google Patents

Sammensætning til behandling af vævslæsioner Download PDF

Info

Publication number
DK3302523T3
DK3302523T3 DK16727365T DK16727365T DK3302523T3 DK 3302523 T3 DK3302523 T3 DK 3302523T3 DK 16727365 T DK16727365 T DK 16727365T DK 16727365 T DK16727365 T DK 16727365T DK 3302523 T3 DK3302523 T3 DK 3302523T3
Authority
DK
Denmark
Prior art keywords
treatment
composition
tissue lesions
lesions
tissue
Prior art date
Application number
DK16727365T
Other languages
English (en)
Inventor
Denis Barritault
Original Assignee
Organes Tissus Regeneration Reparation Remplacement
Denis Barritault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organes Tissus Regeneration Reparation Remplacement, Denis Barritault filed Critical Organes Tissus Regeneration Reparation Remplacement
Application granted granted Critical
Publication of DK3302523T3 publication Critical patent/DK3302523T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16727365T 2015-05-28 2016-05-26 Sammensætning til behandling af vævslæsioner DK3302523T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305807.8A EP3097922A1 (fr) 2015-05-28 2015-05-28 Composition pour le traitement des lesions tissulaires
PCT/EP2016/061906 WO2016189088A1 (fr) 2015-05-28 2016-05-26 Composition pour le traitement des lesions tissulaires

Publications (1)

Publication Number Publication Date
DK3302523T3 true DK3302523T3 (da) 2019-11-04

Family

ID=53269418

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16727365T DK3302523T3 (da) 2015-05-28 2016-05-26 Sammensætning til behandling af vævslæsioner

Country Status (17)

Country Link
US (1) US11351190B2 (da)
EP (3) EP3097922A1 (da)
JP (1) JP2018520115A (da)
KR (1) KR20180044235A (da)
CN (1) CN107809999A (da)
AU (1) AU2016266773B2 (da)
CA (1) CA2987547A1 (da)
DK (1) DK3302523T3 (da)
ES (1) ES2755055T3 (da)
IL (1) IL255694B (da)
MX (1) MX2017015293A (da)
PL (1) PL3302523T3 (da)
PT (1) PT3302523T (da)
RU (1) RU2721116C2 (da)
SI (1) SI3302523T1 (da)
WO (1) WO2016189088A1 (da)
ZA (1) ZA201707813B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804736A4 (en) 2018-06-05 2022-03-30 Medipost Co., Ltd. PHARMACEUTICAL COMPOSITION WITH MESENCHYMAL STEM CELLS AS AN EFFECTIVE INGREDIENT TO PREVENT OR TREAT AN INFLAMMATORY DISEASE
EP3685822A1 (fr) * 2019-01-24 2020-07-29 Organes Tissus Régénération Réparation Remplacement Composition cosmetique/dermatologique
FR3096579B1 (fr) * 2019-05-27 2023-05-05 Organes Tissus Regeneration Reparation Remplacement composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
CN110755597B (zh) * 2019-10-24 2023-07-07 广州市希丽生物科技服务有限公司 用于预防和治疗类风湿性关节炎的外用药物组合物
JP2023517579A (ja) * 2020-03-09 2023-04-26 オルガンズ ティシューズ リジェネレーション リパレーション レムプレースメント － オーティーアール３ 呼吸器系の病変の治療のための組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
FR2718025B1 (fr) 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux.
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
FR2781485B1 (fr) * 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
RU2132187C1 (ru) * 1998-11-12 1999-06-27 Антипов Борис Геннадиевич Способ лечения заболеваний кожи и слизистых оболочек и магнитоактивное органическое соединение железа, используемое в нем
US6361985B1 (en) 1999-01-12 2002-03-26 Zymogenetics, Inc. Beta-1,3-galactosyltransferase homolog, ZNSSP6
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AU2003232152A1 (en) 2002-05-30 2003-12-19 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
US20060257449A1 (en) 2005-05-16 2006-11-16 Didier Billy Methods, compositions, systems, and devices for bone fusion
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
BRPI0805852A8 (pt) 2008-09-05 2021-06-29 Univ Rio De Janeiro polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento
JP6336909B2 (ja) * 2011-10-14 2018-06-06 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 神経変性疾患の診断、予後予測又は治療の方法
EP3097928A1 (fr) * 2015-05-28 2016-11-30 Organes Tissus Régénération Réparation Remplacement Composition pour le traitement des lesions cerebrales

Also Published As

Publication number Publication date
ZA201707813B (en) 2018-12-19
MX2017015293A (es) 2018-05-02
RU2017140049A3 (da) 2019-08-27
CN107809999A (zh) 2018-03-16
EP3302523B1 (fr) 2019-09-11
WO2016189088A1 (fr) 2016-12-01
EP3626256A1 (fr) 2020-03-25
RU2721116C2 (ru) 2020-05-15
EP3302523A1 (fr) 2018-04-11
JP2018520115A (ja) 2018-07-26
CA2987547A1 (fr) 2016-12-01
EP3626256C0 (fr) 2023-08-09
PL3302523T3 (pl) 2020-03-31
US20180125880A1 (en) 2018-05-10
EP3097922A1 (fr) 2016-11-30
ES2755055T3 (es) 2020-04-21
IL255694B (en) 2021-02-28
IL255694A (en) 2018-01-31
KR20180044235A (ko) 2018-05-02
AU2016266773B2 (en) 2022-01-06
EP3626256B1 (fr) 2023-08-09
SI3302523T1 (sl) 2019-12-31
US11351190B2 (en) 2022-06-07
PT3302523T (pt) 2019-11-05
RU2017140049A (ru) 2019-06-28
AU2016266773A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3261726T3 (da) Sammensætning til behandling af acne
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3307267T3 (da) Behandling af multipel sklerose
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3166628T3 (da) Terapeutisk anvendelse af knoglemorfogenetiske proteiner
DK3185867T3 (da) Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3302523T3 (da) Sammensætning til behandling af vævslæsioner
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin